Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ETHACRYNIC ACID 25 MG TABLET

ethacrynic acid
$0.9935per EA

Strength

25 mg/1

Manufacturer

Oceanside Pharmaceuticals

NDC

68682001110

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

9/17/2025

Active Ingredients

ETHACRYNIC ACID

Approval Type

Authorized Generic (NDA)

FDA Application

NDA016092

On Market Since

1/10/1967

Pharmacological Classes

Increased Diuresis at Loop of Henle
Loop Diuretic

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

-22.6%

3Y

-60.7%

5Y

-82.5%

All

-90.1%

Generic Alternatives

1 alternative • Same active ingredient

EDECRIN 25 MG TABLET
Brand
25010021515•Bausch Health US LLC
$21.7231
+2087% more

Related Drugs

Same classification

FUROSEMIDE 20 MG TABLET
Generic
00054429725•Hikma Pharmaceuticals USA Inc.
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
00054429731•Hikma Pharmaceuticals USA Inc.
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
00054829725•Hikma Pharmaceuticals USA Inc.
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
00904717761•Major Pharmaceuticals
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
43547040110•Solco Healthcare US LLC
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
43547040111•Solco Healthcare US LLC
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
59651079601•Aurobindo Pharma Limited
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
59651079699•Aurobindo Pharma Limited
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
62135075390•Chartwell RX LLC
$0.0270
per EA
FUROSEMIDE 20 MG TABLET
Generic
64980056201•Rising Pharma Holdings Inc.
$0.0270
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy